155 related articles for article (PubMed ID: 34873228)
21. Somatostatin analogues reduce liver volume in polycystic liver disease.
van Keimpema L; de Man RA; Drenth JP
Gut; 2008 Sep; 57(9):1338-9. PubMed ID: 18719151
[No Abstract] [Full Text] [Related]
22. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
[TBL] [Abstract][Full Text] [Related]
23. Medical therapy for polycystic liver disease.
Khan S; Dennison A; Garcea G
Ann R Coll Surg Engl; 2016 Jan; 98(1):18-23. PubMed ID: 26688394
[TBL] [Abstract][Full Text] [Related]
24. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.
Suwabe T; Barrera FJ; Rodriguez-Gutierrez R; Ubara Y; Hogan MC
PLoS One; 2021; 16(9):e0257606. PubMed ID: 34559824
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
Hogan MC; Masyuk T; Bergstralh E; Li B; Kremers WK; Vaughan LE; Ihrke A; Severson AL; Irazabal MV; Glockner J; LaRusso NF; Torres VE
Mayo Clin Proc; 2015 Aug; 90(8):1030-7. PubMed ID: 26166166
[TBL] [Abstract][Full Text] [Related]
27. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin analogues for treatment of polycystic liver disease.
Gevers TJ; Drenth JP
Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
[TBL] [Abstract][Full Text] [Related]
29. Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.
Dekker SEI; Bierau J; Giera M; Blomberg N; Drenth JPH; Mayboroda OA; de Fijter JW; Soonawala D;
Eur J Clin Invest; 2024 Apr; 54(4):e14147. PubMed ID: 38071418
[TBL] [Abstract][Full Text] [Related]
30. Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.
Sun L; Yu CY; Mackey LV; Coy DH
Curr Top Med Chem; 2015; 16(2):133-40. PubMed ID: 26126910
[TBL] [Abstract][Full Text] [Related]
31. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
Caroli A; Antiga L; Cafaro M; Fasolini G; Remuzzi A; Remuzzi G; Ruggenenti P
Clin J Am Soc Nephrol; 2010 May; 5(5):783-9. PubMed ID: 20185596
[TBL] [Abstract][Full Text] [Related]
32. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.
Myint TM; Rangan GK; Webster AC
Nephrology (Carlton); 2014 Apr; 19(4):217-26. PubMed ID: 24460701
[TBL] [Abstract][Full Text] [Related]
33. Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial.
Chrispijn M; Drenth JP
Trials; 2011 Nov; 12():246. PubMed ID: 22104015
[TBL] [Abstract][Full Text] [Related]
34. Randomized intervention studies in human polycystic kidney and liver disease.
Schrier RW
J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043
[No Abstract] [Full Text] [Related]
35. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.
Ruggenenti P; Remuzzi A; Ondei P; Fasolini G; Antiga L; Ene-Iordache B; Remuzzi G; Epstein FH
Kidney Int; 2005 Jul; 68(1):206-16. PubMed ID: 15954910
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.
Temmerman F; Gevers T; Ho TA; Vanslembrouck R; Coudyzer W; van Pelt J; Bammens B; Pirson Y; Drenth JP; Nevens F
Aliment Pharmacol Ther; 2013 Aug; 38(4):397-406. PubMed ID: 23799922
[TBL] [Abstract][Full Text] [Related]
38. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
39. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
Lantinga MA; D'Agnolo HM; Casteleijn NF; de Fijter JW; Meijer E; Messchendorp AL; Peters DJ; Salih M; Spithoven EM; Soonawala D; Visser FW; Wetzels JF; Zietse R; Drenth JP; Gansevoort RT;
Drug Saf; 2017 Feb; 40(2):153-167. PubMed ID: 27995519
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus reduces polycystic liver volume in ADPKD patients.
Qian Q; Du H; King BF; Kumar S; Dean PG; Cosio FG; Torres VE
J Am Soc Nephrol; 2008 Mar; 19(3):631-8. PubMed ID: 18199797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
